While the addition of filibuvir to pegIFN/ribavirin improved on-treatment virologic response parameters , this did not translate into improved SVR rates due to a high rate of virologic relapse following completion of therapy ( 300 mg : 35.9 % ; 600 mg : 42.9 % ; placebo : 25.4 % ) .